



Assessing Novel Tobacco Products

Guest Editor:

Dr. Kenneth M. Taylor

US FDA, Ctr Tobacco Prod,
10903 New Hampshire Ave,
Silver Spring, MD 20993, USA
kenneth.taylor@fda.hhs.gov

Deadline for manuscript
submissions:

10 October 2022

Message from the Guest Editor

Tobacco use remains a leading cause of preventable disease, disability, and death. In May 2020, the World Health Organization (WHO) reported that tobacco use was responsible for greater than 8 million annual deaths globally.

The 2018 United States National Academies of Sciences, Engineering, and Medicine report, “The Public Health Consequences of E-cigarettes”, found substantial evidence that use of ENDS leads to dependence; however, there is only moderate evidence that the risk and severity of dependence are lower for ENDS than for combusted tobacco cigarettes.

This Toxics Special Issue welcomes research that aims to characterize and understand novel tobacco products along with their related health effects. Research studying the general use of flavors in tobacco products is also of interest. This Special Issue aims to add to the science that will inform tobacco control policy and regulatory actions on emerging tobacco products such as ENDS, HTPs, and novel smokeless tobacco products.



mdpi.com/si/88570

Special Issue